|

Novel Approach to Radiotherapy in Locally Advanced Lung Cancer Concomitant Navelbine®

RECRUITINGN/ASponsored by Olfred Hansen
Actively Recruiting
PhaseN/A
SponsorOlfred Hansen
Started2015-01
Est. completion2029-10
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT02354274

Summary

To investigate the effect of escalation of radiation dose to tumor and lymph nodes based on an inhomogeneous dose distribution controlled by FDG-PET positive areas compared to a standard homogeneous dose spread

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients with histologically or cytologically proven locally advanced NSCLC stage IIB to IIIB
* Performance status 0-1
* Able to comply with treatment and follow study and follow-up procedures
* Women must have negative pregnancy test
* Signed, informed consent
* Plan for radiotherapy with conventional 66 Gy/ 33 F, which meets all dosing limits two normal tissue must be available

Exclusion Criteria:

* Any unstable systemic disorder (including infection , unstable angina, congestive heart failure , severe liver , kidney or metabolic disease)
* Need for nasal oxygen
* Former thoracic radiotherapy, unless there is no significant overlap with previous fields
* Any other active malignant disease
* Unable to take oral medications or needing intravenous nutrition
* Ulcer
* Nursing women

Conditions3

CancerLung CancerNSCLC

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.